Bio (AAVantgarde), a clinical-stage, biotechnology company pioneering therapies for inherited retinal diseases (IRDs), today announced the successful closing of a $141 million (€122 million) Series B ...

Alexander Van der Bellen will leave the Hofburg in 2028. Who will succeed the Federal President? The parties are putting ...

At the heart of this performance lies the company's cryptocurrency strategy. With an average acquisition cost of $74,032 per Bitcoin and current market values substantially higher, MicroStrategy has ...